Axsome Therapeutics, Inc. (AXSM) [Rocket]

Date Filed

Type

Description

07/21/2022

Financial Statements and Exhibits  Interactive Data

Docs:

"Consent of Independent Auditor We consent to the incorporation by reference in the registration statements on Form S-3 and Form S-8 of Axsome Therapeutics, Inc. of our report dated May 3, 2022 with respect to the abbreviated financial statements of the Sunosi product of Jazz Pharmaceuticals plc, which report appears in the Form 8-K/A of Axsome Therapeutics, Inc. filed July 21, 2022. /s/ KPMG Dublin, Ireland July 21, 2022",
"SUNOSI® Abbreviated Financial Statements As of and for the Years Ended December 31, 2021 and 2020 Index to Abbreviated Financial Statements Page Independent Auditors’ Report 2 Abbreviated Financial Statements: Statements of Assets Acquired 4 Statements of Revenues and Direct Expenses 5 Notes to Abbreviated Financial Statements 6 INDEPENDENT AUDITORS’ REPORT The Board of Directors Jazz Pharmaceuticals plc: REPORT ON ABBREVIATED FINANCIAL STATEMENTS OF THE SUNOSI PRODUCT OF JAZZ PHARMACEUTICALS PLC Opinion We have audited the abbreviated financial statements of the Sunosi product of Jazz Pharmaceuticals plc , which comprise the statement of assets acquired as of December 31, 2021 and 2020, and the related statement of revenues and direct expenses for each of the years then ended, and the re...",
"Index to Unaudited Abbreviated Financial Statements Page Unaudited Abbreviated Financial Statements: Statements of Assets Acquired 2 Statements of Revenues and Direct Expenses 3 Notes to Unaudited Abbreviated Financial Statements 4 Sunosi® Statements of Assets Acquired March 31, 2022 December 31, 2021 Assets Acquired Intangible assets, net $ 72,279 $ 74,243 Inventories, net 21,163 21,557 Other current assets 378 412 Total assets acquired $ 93,820 $ 96,212 The accompanying notes are an integral part of these unaudited abbreviated financial statements. 2 Sunosi® Statements of Revenues and Direct Expenses Three Months Ended March 31, 2022 2021 Product sales, net $ 15,878 $ 11,606 Direct expenses: Cost of product sales 4,178 2,074 Selling, general and administrative 35,288 66,347 Research ...",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 25, 2022, Axsome Therapeutics, Inc. entered into an Asset Purchase Agreement with Jazz Pharmaceuticals plc, pursuant to which the Company will acquire Sunosi from Jazz Pharmaceuticals . The acquisition of Sunosi will occur in two separate closings. The sale and purchase of Specified Initial Assets as defined and contemplated by the Purchase Agreement occurred on May 9, 2022 , following the satisfaction or waiver of the closing conditions under the Purchase Agreement. The sale and purchase of Specified Ex-U.S. Assets contemplated by the Purchase Agreement is expected to occur during the fourth quarter of 2022 . The following unaudited pro forma condensed combined financial statements of Axsome and Sunosi present the combin..."

03/31/2022

8-K/A

Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data

Docs:

"ASSET PURCHASE AGREEMENT between: Jazz Pharmaceuticals plc, a public limited liability corporation organized under the laws of Ireland; and Axsome Therapeutics, Inc., a Delaware corporation. Dated as of March 25, 2022 2 Table of Contents Page SECTION 1. Sale and Purchase of Specified Initial Assets. 1 1.1 Sale and Purchase of Specified Initial Assets 1 1.2 Excluded Assets 3 1.3 Initial Purchase Price 4 1.4 Excluded Liabilities 4 1.5 Initial Ancillary Agreements 5 1.6 Initial Closing 5 1.7 Purchaser Guarantee 5 SECTION 2. Sale and Purchase of Specified Ex-U.S ASSETS 6 2.1 Sale and Purchase of Specified Ex-U.S. Assets 6 2.2 Ex-U.S. Purchase Price 7 2.3 Additional Ancillary Agreements 7 2.4 Final Closing 7 2.5 Later Discovered Contracts 8 SECTION 3. Tax Matters; Allocation of Final Purchase P..."

09/21/2020

8-K/A

Other Events, Financial Statements and Exhibits  Interactive Data

Docs:

"Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting"